Adverse drug reactions induced by valproic acid

Clinical Biochemistry

Volumn 46, Issue 15, 2013, Pages 1323-1338

  Nanau, Radu M ^a   Neuman, Manuela G ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adverse drug reactions; Drug monitoring; Hepatocytotoxicity; Mitochondrial toxicity; Valproic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; AMITRIPTYLINE; AMYLASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBAMAZEPINE; CARNITINE; CHLOROTHIAZIDE; CHOLESTEROL; CILASTATIN PLUS IMIPENEM; CREATININE; CYTOCHROME C OXIDASE; CYTOCHROME P450; DEXAMETHASONE; DIAZEPAM; ETIRACETAM; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; IMMUNOGLOBULIN; LAMOTRIGINE; PHENIRAMINE; PHENOBARBITAL; PHENYTOIN; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; UNINDEXED DRUG; VALPROIC ACID; VITAMIN D; XENOBIOTIC AGENT;

ABDOMINAL OBESITY; AGITATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALPERS DISEASE; AMYLASE BLOOD LEVEL; ANEMIA; ARTERIAL WALL THICKNESS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATAXIA; AUDITORY HALLUCINATION; BILIRUBIN BLOOD LEVEL; BIPOLAR DISORDER; BODY MASS; BODY SURFACE; BONE DENSITY; BONE MARROW TOXICITY; BRADYKINESIA; BRAIN DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTATIC HEPATITIS; CHOLESTEROL BLOOD LEVEL; CHRONIC LIVER DISEASE; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; COGNITION; COHORT ANALYSIS; COMMON CAROTID ARTERY; COMPLEX PARTIAL SEIZURE; CONFUSION; CONVULSION; CREATININE BLOOD LEVEL; CROSS REACTION; DEMENTIA; DEPRESSION; DIABETIC NEUROPATHY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DISORIENTATION; DIZZINESS; DNA BINDING; DNA SYNTHESIS; DRESS SYNDROME; DROWSINESS; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSLIPIDEMIA; ECHOGRAPHY; ENZYME ACTIVITY; EPIDERMOLYSIS; EPILEPTIC STATE; ERYTHEMA MULTIFORME; EYELID EDEMA; FANCONI RENOTUBULAR SYNDROME; FATALITY; FATIGUE; FATTY ACID OXIDATION; FIRST TRIMESTER PREGNANCY; FOOD AND DRUG ADMINISTRATION; FULMINANT HEPATIC FAILURE; GENETIC POLYMORPHISM; GENOTYPE; GLIOBLASTOMA; GLUCOSE BLOOD LEVEL; HEADACHE; HEARING IMPAIRMENT; HEPATIC ENCEPHALOPATHY; HEPATOMEGALY; HERPES SIMPLEX VIRUS; HISTOLOGY; HUMAN; HYPERAMMONEMIA; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; HYPERKERATOSIS; HYPERLEPTINEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; HYPERTROPHIC CARDIOMYOPATHY; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; IN VITRO STUDY; INSULIN RESISTANCE; INTERSTITIAL NEPHRITIS; JAUNDICE; KIDNEY BIOPSY; KIDNEY CLEARANCE; KIDNEY DEVELOPMENT; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; KIDNEY TUBULE DISORDER; LACTIC ACIDOSIS; LEIGH DISEASE; LETHARGY; LEUKOPENIA; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; LUNG HEMORRHAGE; MACULOPAPULAR RASH; MAINTENANCE DRUG DOSE; MANIA; MEDLINE; MENTAL PATIENT; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL TOXICITY; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MYOCLONUS EPILEPSY; NEURAL TUBE DEFECT; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OPEN STUDY; OPHTHALMOPLEGIA; OSTEOMALACIA; OVARY POLYCYSTIC DISEASE; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PANCREAS PSEUDOCYST; PARKINSONISM; PERIPHERAL NEUROPATHY; PHENOTYPE; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROTHROMBIN TIME; PRURITUS; PYRAMIDAL SIGN; RASH; RESPIRATORY CHAIN; RETINITIS PIGMENTOSA; RETT SYNDROME; REVIEW; REYE SYNDROME; RISK FACTOR; SIMPLE PARTIAL SEIZURE; SPLENOMEGALY; STEVENS JOHNSON SYNDROME; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; TERATOGENICITY; THERAPY; THROMBOCYTOPENIA; THYROID FUNCTION; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN DEFICIENCY; VOMITING; WEIGHT GAIN; WHITE MATTER;

ADR; ADVERSE DRUG REACTION; ADVERSE DRUG REACTIONS; AED; AHS; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALP; ALPERS-HUTTENLOCHER SYNDROME; ALT; ANTIEPILEPTIC DRUG; ASPARTATE AMINOTRANSFERASE; AST; CI; CONFIDENCE INTERVAL; CYP; CYTOCHROME P450; DRESS; DRUG MONITORING; DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS; HEPATOCYTOTOXICITY; HHV; HUMAN HERPES VIRUS; INTELLIGENCE QUOTIENT; IQ; MELAS; MITOCHONDRIAL DNA POLYMERASE Γ; MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS AND STROKE; MITOCHONDRIAL TOXICITY; ODDS RATIO; OR; POLG; SCAR; SEVERE CUTANEOUS ADVERSE REACTION; SJS; STEVENS-JOHNSON SYNDROME; TEN; TOXIC EPIDERMAL NECROLYSIS; VALPROIC ACID; VPA; Γ-GLUTAMYL TRANSPEPTIDASE; Γ-GTP;

ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; DRUG HYPERSENSITIVITY; ENDOCRINE SYSTEM; EPILEPSY; HUMANS; HYPERAMMONEMIA; LIVER; MITOCHONDRIA; NERVOUS SYSTEM; PSYCHOTIC DISORDERS; TERATOGENESIS; VALPROIC ACID;

EID: 84884355674     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.06.012     Document Type: Review

References (311)

1. National Institutes of Health Valproic Acid: MedlinePlus Drug Information Last Accessed Nov 29 2012. http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682412.html.
2. Bialer M. Why are antiepileptic drugs used for nonepileptic conditions?. Epilepsia 2012, 53(Suppl. 7):26-33.
3. Hsieh L.P., Huang C.Y. Antiepileptic drug utilization in Taiwan: analysis of prescription using National Health Insurance database. Epilepsy Res 2009, 84:21-27.
4. Tsiropoulos I., Andersen M., Hallas J. Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis. Pharmacoepidemiol Drug Saf 2009, 18:483-491.
5. Soares-Weiser K., Bravo Vergel Y., Beynon S., Dunn G., Barbieri M., Duffy S., et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technol Assess 2007, 11:iii-206.
6. Haddad P.M., Das A., Ashfaq M., Wieck A. A review of valproate in psychiatric practice. Expert Opin Drug Metab Toxicol 2009, 5:539-551.
7. Terbach N., Williams R.S. Structure-function studies for the panacea, valproic acid. Biochem Soc Trans 2009, 37:1126-1132.
8. Vasudev K., Mead A., Macritchie K., Young A.H. Valproate in acute mania: is our practice evidence based?. Int J Health Care Qual Assur 2012, 25:41-52.
9. Blumenfeld A., Gennings C., Cady R. Pharmacological synergy: the next frontier on therapeutic advancement for migraine. Headache 2012, 52:636-647.
10. Cuvellier J.C. Antiepileptic drugs for the prevention of pediatric migraine. Rev Neurol (Paris) 2009, 165:1002-1009.
11. Tan J., Cang S., Ma Y., Petrillo R.L., Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010, 3:5.
12. Zhang X.Z., Li X.J., Zhang H.Y. Valproic acid as a promising agent to combat Alzheimer's disease. Brain Res Bull 2010, 81:3-6.
13. Schwarz C., Volz A., Li C., Leucht S. Valproate for schizophrenia. Cochrane Database Syst Rev 2008, 3:CD004028.
14. Larrison A.L., Babin S.L., Xing Y., Patel S.S., Wassef A.A., Sereno A.B. Effects of adjunct valproic acid on clinical symptoms and saccadic eye movements in schizophrenia. Hum Psychopharmacol 2011, 26:517-525.
15. Wilner A.N., Sharma B.K., Soucy A., Krueger A. Health plan paid cost of epilepsy in 2009 in the U.S. Epilepsy Behav 2012, 25:412-416.
16. Jankovic S.M., Dostic M. Choice of antiepileptic drugs for the elderly: possible drug interactions and adverse effects. Expert Opin Drug Metab Toxicol 2012, 8:81-91.
17. Yamada M., Welty T.E. Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies. Ann Pharmacother 2011, 45:1406-1415.
18. Perucca E., Albani F., Capovilla G., Bernardina B.D., Michelucci R., Zaccara G. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs. Epilepsia 2006, 47(Suppl. 5):16-20.
19. Zimmerman H.J., Ishak K.G. Antiepileptic drugs. Drug-induced hepatotoxicity 1996, 637-662. Springer-Verlag, Berlin. R.G. Cameron, G. Feuer, F.A. de la Iglesia (Eds.).
20. Neuman M.G., Shear N.H., Jacobson-Brown P.M., Katz G.G., Neilson H.K., Malkiewicz I.M., et al. CYP2E1-mediated modulation of valproic acid-induced hepatocytotoxicity. Clin Biochem 2001, 34:211-218.
21. Dreifuss F.E., Langer D.H. Hepatic considerations in the use of antiepileptic drugs. Epilepsia 1987, 28(Suppl. 2):S23-S29.
22. Njølstad P.R., Skjeldal O.H., Agsteribbe E., Huckriede A., Wannaq E., Søvik O., et al. Medium chain acyl-CoA dehydrogenase deficiency and fatal valproatetoxicity. Pediatr Neurol 1997, 16:160-162.
23. Glasgow A.M., Chase H.P. Production of the features of Reye's syndrome in rats with 4-pentenoic acid. Pediatr Res 1975, 9:133-138.
24. Moore J.R., Williams T.H.C., Talbot F.C., Tanner M.S. Heterozygous antitrypsin deficiency and valproate hepatotoxicity. Lancet 1984, 1:221.
25. Kesterson J.W., Granneman G.R., Machinist J.M. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology 1984, 4:1143-1152.
26. Sugimoto T., Woo M., Nishida N., Takeuchi T., Sakane Y., Kobayashi Y. Hepatotoxicity in rat following administration of valproic acid. Epilepsia 1987, 28:142-146.
27. Kiang T.K., Teng X.W., Karagiozov S., Surendradoss J., Chang T.K., Abbott F.S. Role of oxidative metabolism in the effect of valproic acid on markers of cell viability, necrosis, and oxidative stress in sandwich-cultured rat hepatocytes. Toxicol Sci 2010, 118:501-509.
28. Kiang T.K., Teng X.W., Surendradoss J., Karagiozov S., Abbott F.S., Chang T.K. Glutathione depletion by valproic acid in sandwich-cultured rat hepatocytes: role of biotransformation and temporal relationship with onset of toxicity. Toxicol Appl Pharmacol 2011, 252:318-324.
29. Luís P.B., Ruiter J.P., Ofman R., Ijlst L., Moedas M., Diogo L., et al. Valproic acid utilizes the isoleucine breakdown pathway for its complete β-oxidation. Biochem Pharmacol 2011, 82:1740-1746.
30. Aires C.C., van Cruchten A., Ijlst L., de Almeida I.T., Duran M., Wanders R.J., et al. New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. J Hepatol 2011, 55:426-434.
31. Surendradoss J., Chang T.K., Abbott F.S. Assessment of the role of in situ generated (E)-2,4-diene-valproic acid in the toxicity of valproic acid and (E)-2-ene-valproic acid in sandwich-cultured rat hepatocytes. Toxicol Appl Pharmacol 2012, 264:413-422.
32. Ferrajolo C., Capuano A., Verhamme K.M., Schuemie M., Rossi F., et al. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. Br J Clin Pharmacol 2010, 70:721-728.
33. Zeng K., Wang X., Xi Z., Yan Y. Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients. Clin Neurol Neurosurg 2010, 112:291-295.
34. Ghozzi H., Hakim A., Sahnoun Z., Ben Mahmoud L., Atheymen R., Hammami S., et al. Relationship between plasma concentrations of valproic acid and hepatotoxicity in patients receiving high doses. Rev Neurol (Paris) 2011, 167:600-606.
35. Bowden C.L., Mosolov S., Hranov L., Chen E., Habil H., Kongsakon R., et al. Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. Int Clin Psychopharmacol 2010, 25:60-67.
36. Kochar D.K., Rawat N., Agrawal R.P., Vyas A., Beniwal R., Kochar S.K., et al. Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. QJM 2004, 97:33-38.
37. Neyns B., Hoorens A., Stupp R. Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide. Acta Neurol Belg 2008, 108:131-134.
38. Mata Zubillaga D., Prieto Espuñes S., Ferrero de la Mano L., Herrero Mendoza B. Valproic acid induced-idiosyncratic hepatotoxicity. An Pediatr (Barc) 2008, 69:492-493.
39. Zafrani E.S., Berthelot P. Sodium valproate in the induction of unusual hepatotoxicity. Hepatology 1982, 2:648-649.
40. Zimmerman H.J., Ishak K.G. Valproate-induced hepatic injury: analyses of 23 fatal cases. Hepatology 1982, 2:591-597.
41. Scheffner D., König S., Rauterberg-Ruland I., Kochen W., Hofmann W.J., Unkelbach S. Fatal liver failure in 16 children with valproate therapy. Epilepsia 1988, 29:530-542.
42. Dreifuss F.E., Langer D.H., Moline K.A., Maxwell J.E. Valproic acid hepatic fatalities. II. US experience since 1984. Neurology 1989, 39:201-207.
43. Luef G., Rauchenzauner M., Waldmann M., Sturm W., Sandhofer A., Seppi K., et al. Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res 2009, 86:42-47.
44. Verrotti A., Di Marco G., la Torre R., Pelliccia P., Chiarelli F. Nonalcoholic fatty liver disease during valproate therapy. Eur J Pediatr 2009, 168:1391-1394.
45. Verrotti A., Agostinelli S., Parisi P., Chiarelli F., Coppola G. Nonalcoholic fatty liver disease in adolescents receiving valproic acid. Epilepsy Behav 2011, 20:382-385.
46. Colletti R.B., Trainer T.D., Krawisz B.R. Reversible valproate fulminant hepatic failure. J Pediatr Gastroenterol Nutr 1986, 5:990-994.
47. Lewis J.H., Zimmerman H.J., Garrett C.T., Rosenburg E. Valproate-induced hepatic steatogenesis in rats. Hepatology 1982, 2:870-873.
48. Finsterer J., Segall L. Drugs interfering with mitochondrial disorders. Drug Chem Toxicol 2010, 33:138-151.
49. Finsterer J., Zarrouk Mahjoub S. Epilepsy in mitochondrial disorders. Seizure 2012, 21:316-321.
50. Finsterer J., Zarrouk Mahjoub S. Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders. Expert Opin Drug Metab Toxicol 2012, 8:71-79.
51. Lam C.W., Lau C.H., Williams J.C., Chan Y.W., Wong L.J. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr 1997, 156:562-564.
52. Krähenbühl S., Brandner S., Kleinle S., Liechti S., Straumann D. Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver 2000, 20:346-348.
53. Rasmussen M., Sanengen T., Skullerud K., Kvittingen E.A., Skjeldal O.H. Evidence that Alpers-Huttenlocher syndrome could be a mitochondrial disease. J Child Neurol 2000, 15:473-477.
54. Naviaux R.K., Nguyen K.V. POLG mutations associated with Alpers' syndrome and mitochondrial DNA depletion. Ann Neurol 2004, 55:706-712.
55. Saneto R.P., Lee I.C., Koenig M.K., Bao X., Weng S.W., Naviaux R.K., et al. POLG DNA testing as an emerging standard of care before institutingvalproic acid therapy for pediatric seizure disorders. Seizure 2010, 19:140-146.
56. Pronicka E., Weglewska-Jurkiewicz A., Pronicki M., Sykut-Cegielska J., Kowalski P., Pajdowska M., et al. Drug-resistant epilepsia and fulminant valproate liver toxicity. Alpers-Huttenlocher syndrome in two children confirmed post mortem by identification of p.W748S mutation in POLG gene. Med Sci Monit 2011, 17:CR203-CR209.
57. Palin E.J., Lesonen A., Farr C.L., Euro L., Suomalainen A., Kaguni L.S. Functional analysis of H. sapiens DNA polymerase gamma spacer mutation W748S with and without common variant E1143G. Biochim Biophys Acta 2010, 1802:545-551.
58. Naviaux R.K., Nyhan W.L., Barshop B.A., Poulton J., Markusic D., Karpinski N.C., et al. Mitochondrial DNA polymerase gamma deficiency and mtDNA depletion in a child with Alpers' syndrome. Ann Neurol 1999, 45:54-58.
59. Stewart J.D., Horvath R., Baruffini E., Ferrero I., Bulst S., Watkins P.B., et al. Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 2010, 52:1791-1796.
60. Kayihan N., Nennesmo I., Ericzon B.G., Németh A. Fatal deterioration of neurological disease after orthotopic liver transplantation forvalproic acid-induced liver damage. Pediatr Transplant 2000, 4:211-214.
61. McFarland R., Hudson G., Taylor R.W., Green S.H., Hodges S., McKiernan P.J., et al. Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase gamma (POLG1). Arch Dis Child 2008, 93:151-153.
62. Simonati A., Filosto M., Savio C., Tomelleri G., Tonin P., Dalla Bernardina B., et al. Features of cell death in brain and liver, the target tissues of progressive neuronal degeneration of childhood with liver disease (Alpers-Huttenlocher disease). Acta Neuropathol 2003, 106:57-65.
63. Bao X., Wu Y., Wong L.J., Zhang Y., Xiong H., Chou P.C., et al. Alpers syndrome with prominent white matter changes. Brain Dev 2008, 30:295-300.
64. Uusimaa J., Hinttala R., Rantala H., Päivärinta M., Herva R., Röyttä M., et al. Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onsetAlpers syndrome and status epilepticus. Epilepsia 2008, 49:1038-1045.
65. Zsurka G., Baron M., Stewart J.D., Kornblum C., Bös M., Sassen R., et al. Clonally expanded mitochondrial DNA mutations in epileptic individuals with mutated DNA polymerase gamma. J Neuropathol Exp Neurol 2008, 67:857-866.
66. Wolf N.I., Rahman S., Schmitt B., Taanman J.W., Duncan A.J., Harting I., et al. Status epilepticus in children with Alpers' disease caused by POLG1 mutations: EEG and MRI features. Epilepsia 2009, 50:1596-1607.
67. Schaller A., Hahn D., Jackson C.B., Kern I., Chardot C., Belli D.C., et al. Molecular and biochemical characterisation of a novel mutation in POLG associated with Alpers syndrome. BMC Neurol 2011, 11:4.
68. Kasiviswanathan R., Longley M.J., Chan S.S., Copeland W.C. Disease mutations in the human mitochondrial DNA polymerase thumb subdomain impart severe defects in mitochondrial DNA replication. J Biol Chem 2009, 284:19501-19510.
69. Chan S.S., Longley M.J., Copeland W.C. The common A467T mutation in the human mitochondrial DNA polymerase (POLG) compromises catalytic efficiency and interaction with the accessory subunit. J Biol Chem 2005, 280:31341-31346.
70. Chan S.S., Longley M.J., Copeland W.C. Modulation of the W748S mutation in DNA polymerase gamma by the E1143Gpolymorphismin mitochondrial disorders. Hum Mol Genet 2006, 15:3473-3483.
71. Tzoulis C., Engelsen B.A., Telstad W., Aasly J., Zeviani M., Winterthun S., et al. The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain 2006, 129:1685-1692.
72. Davidzon G., Mancuso M., Ferraris S., Quinzii C., Hirano M., Peters H.L., et al. POLG mutations and Alpers syndrome. Ann Neurol 2005, 57:921-923.
73. Engelsen B.A., Tzoulis C., Karlsen B., Lillebø A., Laegreid L.M., Aasly J., et al. POLG1 mutations cause a syndromic epilepsy with occipital lobe predilection. Brain 2008, 131:818-828.
74. Nguyen K.V., Sharief F.S., Chan S.S., Copeland W.C., Naviaux R.K. Molecular diagnosis of Alpers syndrome. J Hepatol 2006, 45:108-116.
75. Milone M., Wang J., Liewluck T., Chen L.C., Leavitt J.A., Wong L.J. Novel POLG splice site mutation and optic atrophy. Arch Neurol 2011, 68:806-811.
76. Euro L., Farnum G.A., Palin E., Suomalainen A., Kaguni L.S. Clustering of Alpers disease mutations and catalytic defects in biochemical variants reveal new features of molecular mechanism of the human mitochondrial replicase, Pol γ. Nucleic Acids Res 2011, 39:9072-9084.
77. Wong L.J., Naviaux R.K., Brunetti-Pierri N., Zhang Q., Schmitt E.S., Truong C., et al. Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. Hum Mutat 2008, 29:E150-E172.
78. Stewart J.D., Tennant S., Powell H., Pyle A., Blakely E.L., He L., et al. Novel POLG1 mutations associated with neuromuscular and liver phenotypes in adults and children. J Med Genet 2009, 46:209-214.
79. Tzoulis C., Papingji M., Fiskestrand T., Røste L.S., Bindoff L.A. Mitochondrial DNA depletion in progressive external ophthalmoplegia caused by POLG1 mutations. Acta Neurol Scand Suppl 2009, 120:38-41.
80. van Goethem G., Schwartz M., Löfgren A., Dermaut B., Van Broeckhoven C., Vissing J. Novel POLG mutations in progressive external ophthalmoplegia mimicking mitochondrial neurogastrointestinal encephalomyopathy. Eur J Hum Genet 2003, 11:547-549.
81. Bindoff L.A. Mitochondrial function and pathology in status epilepticus. Epilepsia 2011, 52(Suppl. 8):6-7.
82. Lin C.M., Thajeb P. Valproic acid aggravates epilepsy due to MELAS in a patient with an A3243G mutation of mitochondrial DNA. Metab Brain Dis 2007, 22:105-109.
83. Aharoni S., Traves T.A., Melamed E., Cohen S., Silver E.L. MELAS syndrome associated with both A3243G-tRNALeu mutation and multiple mitochondrial DNA deletions. J Neurol Sci 2010, 296:101-103.
84. Hsu Y.C., Yang F.C., Perng C.L., Tso A.C., Wong L.J., Hsu C.H. Adult-onset of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome presenting as acute meningoencephalitis: a case report. J Emerg Med 2012, 43:e163-e166.
85. Sasarman F., Antonicka H., Shoubridge E.A. The A3243G tRNALeu(UUR) MELAS mutation causes amino acid misincorporation and a combined respiratory chain assembly defect partially suppressed by overexpression of EFTu and EFG2. Hum Mol Genet 2008, 17:3697-3707.
86. Mezghani N., Mnif M., Kacem M., Mkaouar-Rebai E., Hadj Salem I., Kallel N., et al. A whole mitochondrial genome screening in a MELAS patient: a novel mitochondrial tRNA(Val) mutation. Biochem Biophys Res Commun 2011, 407:747-752.
87. Tzoulis C., Bindoff L.A. Melas associated with mutations in the polg1 gene. Neurology 2008, 70:1054.
88. Deschauer M., Turnbull D.M., Taylor R.W. Melas associated with mutations in the polg1 gene. Neurology 2008, 70:1053-1054.
89. Dhamija R., Gavrilova R.H., Wirrell E.C. Valproate-induced worsening of seizures: clue to underlying diagnosis. J Child Neurol 2011, 26:1319-1321.
90. Chopra A., Kolla B.P., Mansukhani M.P., Netzel P., Frye M.A. Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management. Gen Hosp Psychiatry 2012, 34:290-298.
91. Stewart J.T. A case of hyperammonemic encephalopathy after 11years of valproate therapy. J Clin Psychopharmacol 2008, 28:361-362.
92. Alluin A., Jezequel J., Gauthier N., Desmaretz J.L., Canevet C. Acute valproic acid intoxication: interest of a treatment by extracoporeal elimination combined with l-carnitine. Ann Fr Anesth Reanim 2011, 30:752-754.
93. Rupasinghe J., Jasinarachchi M. Progressive encephalopathy with cerebral oedema and infarctions associated with valproate and diazepam overdose. J Clin Neurosci 2011, 18:710-711.
94. Young L., Coffey B.J. Bipolar disorder and valproate-induced hyperammonemic encephalopathy in an adolescent with diabetes. J Child Adolesc Psychopharmacol 2010, 20:449-452.
95. Shan J.C., Hsieh M.H., Liu C.C., Wen C.C., Liu C.M. Clinical alertness to valproic acid-induced hyperammonemia-two case reports. J Psychopharmacol 2010, 24:943-945.
96. LaBuzetta J.N., Yao J.Z., Bourque D.L., Zivin J. Adult nonhepatic hyperammonemia: a case report and differential diagnosis. Am J Med 2010, 123:885-891.
97. Granel B., Gavaret M., Le Baut X., Sautereau N., Rodriguez D., Rossi P., et al. Valproate-induced hyperammonemic encephalopathy. Rev Med Interne 2011, 32:e72-e75.
98. Starer J., Chang G. Hyperammoneic encephalopathy, valproic acid, and benzodiazepine withdrawal: a case series. Am J Drug Alcohol Abuse 2010, 36:98-101.
99. Deutsch S.I., Burket J.A., Rosse R.B. Valproate-induced hyperammonemic encephalopathy and normal liver functions: possible synergism with topiramate. Clin Neuropharmacol 2009, 32:350-352.
100. Chou H.F., Yang R.C., Chen C.Y., Jong Y.J. Valproate-induced hyperammonemic encephalopathy. Pediatr Neonatol 2008, 49:201-204.
101. Abreu L.N., Issler C., Lafer B. Valproate-induced reversible pseudoatrophy of the brain and hyperammonemic encephalopathy in a bipolar patient. Aust N Z J Psychiatry 2009, 43:484-485.
102. Bezinover D., Postula M., Donahue K., Bentzen B., McInerney J., Janicki P.K. Perioperative exacerbation of valproic acid-associated hyperammonemia: a clinical and genetic analysis. Anesth Analg 2011, 113:858-861.
103. Garg R., Sunder R.A. Valproate-induced hyperammonemia and seizures: perioperative concerns. Paediatr Anaesth 2011, 21:1084-1085.
104. Gomez-Ibañez A., Urrestarazu-Bolumburu E., Viteri-Torres C. Hyperammonemic encephalopathy related to valproate, phenobarbital, and topiramate synergism. Epilepsy Behav 2011, 21:480-482.
105. Prins M.C., van Meijel J.J. A case of hyperammonaemic encephalopathy due to valproic acid. Neth J Med 2011, 69:389-391.
106. Bøhmer T., Bøen A., Høymork S.C. Valproate-induced hyperammonemic encephalopathy, rapidly improved by i.v. carnitine and glucose/thiamine. Scand J Gastroenterol 2010, 45:762-763.
107. Ghosh V.B., Kapoor S., Prakash A., Bhatt S. Cerebellar atrophy in a child with valproate toxicity. Indian J Pediatr 2011, 78:999-1001.
108. Khoo C.L., Naik S., Lua R., Chai S.B., Liew A., Sim K. Valproate-induced hyperammonemia in mental retardation: a case report and review of the literature. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:561-562.
109. Sonik P., Hilty D.M., Rossaro L., Bourgeois J.A. Carnitine supplementation for valproate-related hyperammonemia to maintain therapeutic valproate level. J Clin Psychopharmacol 2011, 31:680-682.
110. Hung C.C., Li T.M., Wei I.H., Huang C.C. The real mechanism of VPA-induced hyperammonemia remains unknown. Gen Hosp Psychiatry 2011, 33:84.e3-84.e4.
111. Trojak B., de la Gastine B., Dollfus S. Valproate-induced encephalopathy related to concurrent antimanic medications. J Neuropsychiatry Clin Neurosci 2011, 23:E22-E23.
112. Yagi M., Nakamura T., Okizuka Y., Oyazato Y., Kawasaki Y., Tsuneishi S., et al. Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia. Pediatr Int 2010, 52:744-748.
113. Israel Y., Rubin E. Alcohol-induced liver injury. Drug-induced hepatotoxicity 1996, 611-636. Springer-Verlag, Berlin. R.G. Cameron, G. Feuer, F.A. de la Iglesia (Eds.).
114. Raja M., Azzoni A. Valproate-induced hyperammonaemia. J Clin Psychopharmacol 2002, 22:631-633.
115. Mock C.M., Schwetschenau K.H. Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy. Am J Health Syst Pharm 2012, 69:35-39.
116. Mehndiratta M.M., Mehndiratta P., Phul P., Garg S. Valproate induced non hepatic hyperammonaemic encephalopathy (VNHE)-a study from tertiary care referral university hospital, north India. J Pak Med Assoc 2008, 58:627-631.
117. Bocchetta A., Siddu A., Sardu C., Sarnicola A., Martinelli V. Ammonemia in bipolar patients on maintenance treatment with valproic acid. J Clin Psychopharmacol 2012, 32:148-150.
118. Hottinger A., Sutter R., Marsch S., Rüegg S. Topiramate as an adjunctive treatment in patients with refractory status epilepticus: an observational cohort study. CNS Drugs 2012, 26:761-772.
119. Hamed S.A., Abdella M.M. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status. Epilepsy Res 2009, 86:32-41.
120. Perrott J., Murphy N.G., Zed P.J. l-carnitine for acute valproic acid overdose: a systematic review of published cases. Ann Pharmacother 2010, 44:1287-1293.
121. Rousseau M.C., Montana M., Villano P., Catala A., Blaya J., Valkov M., et al. Valproic acid-induced encephalopathy in very long course treated patients. Brain Inj 2009, 23:981-984.
122. DeWolfe J.L., Knowlton R.C., Beasley M.T., Cofield S., Faught E., Limdi N.A. Hyperammonemia following intravenous valproate loading. Epilepsy Res 2009, 85:65-71.
123. Reye R.D., Morgan G., Baral J. Encephalopathy and fatty degeneration of the viscera. A disease entity in childhood. Lancet 1963, 2:749-752.
124. Sugimoto T., Nishida N., Yasuhara A., Ono A., Sakane Y., Matsumura T. Reye-like syndrome associated with valproic acid. Brain Dev 1983, 5:334-337.
125. Trost L.C., Lemasters J.J. The mitochondrial permeability transition: a new pathophysiological mechanism for Reye's syndrome and toxic liver injury. J Pharmacol Exp Ther 1996, 278:1000-1005.
126. Gerber N., Dickinson R.G., Harland R.C., Lynn R.K., Houghton L.D., Antonias J.I., et al. Reye-like syndrome associated with valproic acid therapy. J Pediatr 1979, 95:142-144.
127. Young R.S., Bergman I., Gang D.L., Richardson E.P. Fatal Reye-like syndrome associated with valproic acid. Ann Neurol 1980, 7:389.
128. Böhles H., Richter K., Wagner-Thiessen E., Schäfer H. Decreased serum carnitine in valproate induced Reye syndrome. Eur J Pediatr 1982, 139:185-186.
129. Murphy J.V., Marquardt K.M., Shug A.L. Valproic acid associated abnormalities of carnitine metabolism. Lancet 1985, 1:820-821.
130. Zimmerman H.J. The spectrum of hepatotoxicity. Perspect Biol Med 1968, 12:135-161.
131. Shear N.H., Spielberg S.P. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 1988, 82:1826-1832.
132. Zimmerman H.J. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver 1999, Lippincott Williams and Wilkins, Philadelphia. 2nd ed.
133. Neuman M.G., Malkiewicz I.M., Shear N.H. A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes. Clin Biochem 2000, 33:517-524.
134. Neuman M.G., Malkiewicz I.M., Phillips E.J., Rachlis A.R., Ong D., Yeung E., et al. Monitoring adverse drug reactions to sulfonamide antibiotics in human immunodeficiency virus-infected individuals. Ther Drug Monit 2002, 24:728-736.
135. Krivoy N., Taer M., Neuman M.G. Antiepileptic drug-induced hypersensitivity syndrome reactions. Curr Drug Saf 2006, 1:289-299.
136. Neuman M., Nicar M. Apoptosis in ibuprofen-induced Stevens-Johnson syndrome. Transl Res 2007, 149:254-259.
137. Neuman M.G., Shear N.H., Malkiewicz I.M., Taeri M., Shapiro L.E., Krivoy N., et al. Immunopathogenesis of hypersensitivity syndrome reactions to sulfonamides. Transl Res 2007, 149:243-253.
138. Neuman M.G., Shear N.H., Malkiewicz I.M., Kessas M., Lee A.W., Cohen L. Predicting possible zonisamide hypersensitivity syndrome. Exp Dermatol 2008, 17:1045-1051.
139. Nanau R.M., Neuman M.G. Ibuprofen-induced hypersensitivity syndrome. Transl Res 2010, 155:275-293.
140. Neuman M.G., Cohen L., Nanau R.M., Hwang P.A. Genetic and immune predictors for hypersensitivity syndrome to antiepileptic drugs. Transl Res 2012, 159:397-406.
141. Pritchett J.C., Nanau R.M., Neuman M.G. The Link between Hypersensitivity Syndrome Reaction Development and Human Herpes Virus-6 Reactivation. Int J Hepatol 2012, 2012:723062.
142. Assier H., Bastuji-Garin S., Revuz J., Roujeau J.C. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol 1995, 131:539-543.
143. Roujeau J.C., Kelly J.P., Naldi L., Rzany B., Stern R.S., Anderson T., et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995, 333:1600-1607.
144. Halevy S., Grossman N. Multiple drug allergy in patients with cutaneous adverse drug reactions diagnosed by in vitro drug-induced interferon-gamma release. Isr Med Assoc J 2008, 10:865-868.
145. Mockenhaupt M., Viboud C., Dunant A., Naldi L., Halevy S., Bouwes Bavinck J.N., et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008, 128:35-44.
146. Yang C.Y., Dao R.L., Lee T.J., Lu C.W., Yang C.H., Hung S.I., et al. Severe cutaneous adverse reactions to antiepileptic drugs in Asians. Neurology 2011, 77:2025-2033.
147. Tennis P., Stern R.S. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997, 49:542-546.
148. Bohan K.H., Mansuri T.F., Wilson N.M. Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care. Pharmacotherapy 2007, 27:1425-1439.
149. Mansur A.T., Pekcan Yaşar S., Göktay F. Anticonvulsant hypersensitivity syndrome: clinical and laboratory features. Int J Dermatol 2008, 47:1184-1189.
150. Li L.M., Russo M., O'Donoghue M.F., Duncan J.S., Sander J.W. Allergic skin rash with lamotrigine and concomitant valproate therapy: evidence for an increased risk. Arq Neuropsiquiatr 1996, 54:47-49.
151. Messenheimer J.A., Giorgi L., Risner M.E. The tolerability of lamotrigine in children. Drug Saf 2000, 22:303-312.
152. Page R.L., O'Neil M.G., Yarbrough D.R., Conradi S. Fatal toxic epidermal necrolysis related to lamotrigine administration. Pharmacotherapy 1998, 18:392-398.
153. Brown T.S., Appel J.E., Kasteler J.S., Callen J.P. Hypersensitivity reaction in a child due to lamotrigine. Pediatr Dermatol 1999, 16:46-49.
154. Matsuo F. Lamotrigine. Epilepsia 1999, 40(Suppl. 5):S30-S36.
155. Wang X.Q., Lang S.Y., Shi X.B., Tian H.J., Wang R.F., Yang F. Cross-reactivity of skin rashes with current antiepileptic drugs in Chinese population. Seizure 2010, 19:562-566.
156. Bin-Nakhi H.A., Sadeq S., Pinto R.G., Habeeb Y. Anticonvulsant hypersensitivity syndrome: report of 2 cases from Kuwait. Med Princ Pract 2003, 12:197-199.
157. Rahman M., Haider N. Anticonvulsant hypersensitivity syndrome from addition of lamotrigine to divalproex. Am J Psychiatry 2005, 162:1021.
158. Chang C.C., Shiah I.S., Yeh C.B., Wang T.S., Chang H.A. Lamotrigine-associated anticonvulsant hypersensitivity syndrome in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:741-744.
159. Dreesman A., Hoorens A., Hachimi-Idrissi S. Multiple organ dysfunction syndrome: infection or hypersensitivity reaction?. Eur J Emerg Med 2010, 17:228-229.
160. Cacoub P., Musette P., Descamps V., Meyer O., Speirs C., Finzi L., et al. The DRESS syndrome: a literature review. Am J Med 2011, 124:588-597.
161. Conilleau V., Dompmartin A., Verneuil L., Michel M., Leroy D. Hypersensitivity syndrome due to 2 anticonvulsant drugs. Contact Dermatitis 1999, 41:141-144.
162. Yun S.J., Lee J.B., Kim E.J., Quan G., Kim S.J., Won Y.H., et al. Drug rash with eosinophilia and systemic symptoms induced by valproate and carbamazepine: formation of circulating auto-antibody against 190-kDa antigen. Acta Derm Venereol 2006, 86:241-244.
163. Ben Salem C., Slim R., Denguezli M., Nouira R., Hmouda H., Bouraoui K. A recurrent drug rash with eosinophilia and systemic symptoms. Pediatr Dermatol 2007, 24:666-668.
164. Albayrak F., Cerrah S., Albayrak A., Dursun H., Yildirim R., Uyanik A. DRESS syndrome with fatal results induced by sodium valproate in a patient with brucellosis and a positive cytoplasmic antineutrophilic cytoplasmic antibody test result. Rheumatol Int 2012, 32:2181-2184.
165. van Zoelen M.A., de Graaf M., van Dijk M.R., Bogte A., van Erpecum K.J., Rockmann H., et al. Valproic acid-induced DRESS syndrome with acute liver failure. Neth J Med 2012, 70:155.
166. Gökçe S., Durmaz O., Celtik C., Aydogan A., Güllüoglu M., Sökücü S. Valproic acid-associated vanishing bile duct syndrome. J Child Neurol 2010, 25:909-911.
167. Levi N., Bastuji-Garin S., Mockenhaupt M., Roujeau J.C., Flahault A., Kelly J.P., et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics 2009, 123:e297-e304.
168. Rzany B., Correia O., Kelly J.P., Naldi L., Auquier A., Stern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999, 353:2190-2194.
169. Mockenhaupt M., Messenheimer J., Tennis P., Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005, 64:1134-1138.
170. Schlienger R.G., Shapiro L.E., Shear N.H. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 1998, 39(Suppl. 7):S22-S26.
171. Chang C.C., Shiah I.S., Chang H.A., Huang S.Y. Toxic epidermal necrolysis with combination lamotrigine and valproate in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:147-150.
172. Knowles S.R., Shapiro L.E., Shear N.H. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999, 21:489-501.
173. Kamada N., Yoneyama K., Togawa Y., Suehiro K., Shinkai H., Yokota M., et al. Toxic epidermal necrolysis with severe hyperbilirubinemia: complete re-epithelialization after bilirubin reduction therapies. J Dermatol 2010, 37:534-536.
174. Roepke S., Treudler R., Anghelescu I., Orfanos C.E., Tebbe B. Valproic acid and hypersensitivity syndrome. Am J Psychiatry 2004, 161:579.
175. Chang Y.C., Lin J.J., Wang H.S., Chou M.L., Hung P.C., Hsieh M.Y. Intravenous valproate for seizures in 137 Taiwanese children-valproate naive and non-naive. Acta Neurol Taiwan 2010, 19:100-106.
176. Roy S., Goel D. Unusual cutaneous reaction with sodium valproate. Neurol India 2009, 57:216-217.
177. Chan H.L., Tan K.C. Fixed drug eruption to three anticonvulsant drugs: an unusual case of polysensitivity. J Am Acad Dermatol 1997, 36:259.
178. Guevara-Campos J., González-De Guevara L., Berardi-Lorenzón M.L., Ibrahim G., Mejías P., Agelvis M.C. Toxic epidermal necrolysis associated to the use of valproic acid. Rev Neurol 2010, 50:444-445.
179. Arévalo-Lorido J.C., Carretero-Gómez J., Bureo-Dacal J.C., Montero-Leal C., Bureo-Dacal P. Antiepileptic drug hypersensitivity syndrome in a patient treated with valproate. Br J Clin Pharmacol 2003, 55:415-416.
180. Kocak S., Girisgin S.A., Gul M., Cander B., Kaya H., Kaya E. Stevens-Johnson syndrome due to concomitant use of lamotrigine and valproic acid. Am J Clin Dermatol 2007, 8:107-111.
181. Ertam I., Sezgin A.O., Unal I. A case with Stevens Johnson syndrome triggered by combination of clobazam, lamotrigine, and valproic acid treatment. Int J Dermatol 2009, 48:98-99.
182. Kamper A.M., Valentijn R.M., Strickler B.H., Purcell P.M. Cutaneous vasculitis induced by sodium valproate. Lancet 1991, 337:497-498.
183. Lasić D., Ivanišević R., Uglešić B., Cvitanović M.Z., Glučina D., Hlevnjak I. Valproate-acid-induced cutaneous leukocytoclastic vasculitis. Psychiatr Danub 2012, 24:215-218.
184. Cogrel O., Beylot-Barry M., Vergier B., Dubus P., Doutre M.S., Merlio J.P., et al. Sodium valproate-induced cutaneous pseudolymphoma followed by recurrence with carbamazepine. Br J Dermatol 2001, 144:1235-1238.
185. Glauser T.A., Cnaan A., Shinnar S., Hirtz D.G., Dlugos D., Masur D., et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12months. Epilepsia 2013, 54:141-155.
186. Viteri C., Codina M., Cobaleda S., Lahuerta J., Barriga J., Morales M.D. Quality of life and treatment satisfaction in Spanish epilepsy patients on monotherapy with lamotrigine or valproic acid. Seizure 2010, 19:432-438.
187. Yu P.M., Zhu G.X., Wu X.Y., Li T., Xu L., Yue L., et al. A 6-month prospective study on efficacy safety and QOL profiles of extended-release formulation of valproate in patients with epilepsy. Seizure 2011, 20:23-26.
188. Arbaizar B., Gómez-Acebo I., Llorca J. Postural induced-tremor in psychiatry. Psychiatry Clin Neurosci 2008, 62:638-645.
189. Olindo S., Belrose G., Gillet N., Rodriguez S., Boxus M., Verlaeten O., et al. Safety of long-term treatment of HAM/TSP patients with valproic acid. Blood 2011, 118:6306-6309.
190. Bondon-Guitton E., Sommet A., Montastruc J.L. Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database. Pharmacopsychiatry 2009, 42:61-65.
191. Gill D., Derry S., Wiffen P.J., Moore R.A. Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2011, 10:CD009183.
192. Marcus R., Khan A., Rollin L., Morris B., Timko K., Carson W., et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 2011, 13:133-144.
193. Gareri P., Lacava R., Cotroneo A., Bambara V., Marigliano N., Castagna A., et al. Valproate-induced delirium in a demented patient. Arch Gerontol Geriatr 2009, 49(Suppl. 1):113-118.
194. Huang C.C., Wei I.H. Unexpected interaction between quetiapine and valproate in patients with bipolar disorder. Gen Hosp Psychiatry 2010, 32:446.e1-446.e2.
195. Özen S., Bülbül I., Soyuçok E. Valproate induced hypoactive delirium in a bipolar disorder patient with psychotic features. Turk Psikiyatri Derg 2010, 21:79-84.
196. Penot J.P., Pradeau F. Iatrogenic dementia and extrapyramidal syndrome: rare adverse effect of valproic acid-aspirin combination. Presse Med 2010, 39:279-280.
197. Sleegers M.J., Beutler J.J., Hardon W.J., Berden J.H., Verhave J.C., Conemans J.M., et al. Reversible rapidly progressive dementia with parkinsonism induced by valproate in a patient with systemic lupus erythematosus. J Am Geriatr Soc 2010, 58:799-801.
198. Evans M.D., Shinar R., Yaari R. Reversible dementia and gait disturbance after prolonged use of valproic acid. Seizure 2011, 20:509-511.
199. Srinivasan S., Lok A.W. Valproate-induced reversible hemichorea. Mov Disord 2010, 25:1511-1512.
200. Bondon-Guitton E., Perez-Lloret S., Bagheri H., Brefel C., Rascol O., Montastruc J.L. Drug-induced parkinsonism: a review of 17years' experience in a regional pharmacovigilance center in France. Mov Disord 2011, 26:2226-2231.
201. Mahmoud F., Tampi R.R. Valproic acid-induced parkinsonism in the elderly: a comprehensive review of the literature. Am J Geriatr Pharmacother 2011, 9:405-412.
202. De Dios C., Fudio S., Lorenzo A. Reversible parkinsonism and cognitive decline due to a possible interaction of valproic acid and quetiapine. J Clin Pharm Ther 2011, 36:430-432.
203. Rosenberg S.L., Chen S., McLaughlin N., El-Dahr S.S. Regulation of kidney development by histone deacetylases. Pediatr Nephrol 2011, 26:1445-1452.
204. Endo A., Fujita Y., Fuchigami T., Takahashi S., Mugishima H. Fanconi syndrome caused by valproic acid. Pediatr Neurol 2010, 42:287-290.
205. Patel S.M., Graff-Radford J., Wieland M.L. Valproate-induced Fanconi syndrome in a 27-year-old woman. J Gen Intern Med 2011, 26:1072-1074.
206. Yoshikawa H., Watanabe T., Abe T. Tubulo-interstitial nephritis caused by sodium valproate. Brain Dev 2002, 24:102-105.
207. Dhillon N., Högler W. Fractures and Fanconi syndrome due to prolonged sodium valproate use. Neuropediatrics 2011, 42:119-121.
208. Leonard H., Downs J., Jian L., Bebbington A., Jacoby P., Nagarajan L., et al. Valproate and risk of fracture in Rett syndrome. Arch Dis Child 2010, 95:444-448.
209. Prohaska E.S., Muzyk A.J., Rivelli S.K. Levocarnitine-induced hypophosphatemia in a hemodialysis patient with acute valproic acid toxicity. J Neuropsychiatry Clin Neurosci 2012, 24:E18-E19.
210. Krishnamoorthy G., Nair R., Sundar U., Kini P., Shrivastava M. Early predisposition to osteomalacia in Indian adults on phenytoin or valproate monotherapy and effective prophylaxis by simultaneous supplementation with calcium and 25-hydroxy vitamin D at recommended daily allowance dosage: a prospective study. Neurol India 2010, 58:213-219.
211. Krishnamoorthy G., Karande S., Ahire N., Mathew L., Kulkarni M. Bone metabolism alteration on antiepileptic drug therapy. Indian J Pediatr 2009, 76:377-383.
212. Triantafyllou N., Lambrinoudaki I., Armeni E., Evangelopoulos E.M., Boufidou F., Antoniou A., et al. Effect of long-term valproate monotherapy on bone mineral density in adults with epilepsy. J Neurol Sci 2010, 290:131-134.
213. Israelian L.A., Lubnin A.Iu., Tseǐtlin A.M., Stepanenko A.Iu., Kazarian A.A., Golovteev A.L., et al. Hemostatic disorders caused by chronic use of valproic acid in neurosurgical patients. Thromboelastographic monitoring. Anesteziol Reanimatol 2010, 4:50-54.
214. Eberl W., Budde U., Bentele K., Christen H.J., Knapp R., Mey A., et al. Acquired von Willebrand syndrome as side effect of valproic acidtherapy in children is rare. Hamostaseologie 2009, 29:137-142.
215. Köse G., Arhan E., Unal B., Ozaydin E., Guven A., Sayli T.R. Valproate-associated coagulopathies in children during short-term treatment. J Child Neurol 2009, 24:1493-1498.
216. Ünal Ö., Deda G., Teber S., Ertem M., Akar N. Thrombophilic risk factors in epileptic children treated with valproic acid. Pediatr Neurol 2009, 40:102-106.
217. Kaczorowska-Hac B., Matheisel A., Maciejka-Kapuscinska L., Wisniewski J., Alska A., Adamkiewicz-Drozynska E., et al. Anemia secondary to valproic acid therapy in a 13-year-old boy: a case report. J Med Case Rep 2012, 6:239.
218. Chakraborty S., Chakraborty J., Mandal S., Ghosal M.K. A rare occurrence of isolated neutropenia with valproic acid: a case report. J Indian Med Assoc 2011, 109:345-346.
219. Hung W.C., Hsieh M.H. Neutropenia associated with the comedication of quetiapine and valproate in 2 elderly patients. J Clin Psychopharmacol 2012, 32:416-417.
220. Chang L.R., Chang H.C., Lin Y.H. Quetiapine- and valproate-associated neutropenia and thrombocytopenia after lamotrigine-induced Steven-Johnson syndrome. J Clin Psychopharmacol 2012, 32:133-134.
221. Rahman A., Mican L.M., Fischer C., Campbell A.H. Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents. Ann Pharmacother 2009, 43:822-830.
222. Vasudev K., Keown P., Gibb I., McAllister-Williams R.H. Hematological effects of valproate in psychiatric patients: what are the risk factors?. J Clin Psychopharmacol 2010, 30:282-285.
223. Chuang Y.C., Chuang H.Y., Lin T.K., Chang C.C., Lu C.H., Chang W.N., et al. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia 2012, 53:120-128.
224. Erdemir A., Cullu N., Yiş U., Demircioǧlu F., Kir M., Cakmakçi H., et al. Evaluation of serum lipids and carotid artery intima media thickness in epileptic children treated with valproic acid. Brain Dev 2009, 31:713-716.
225. Cheng L.S., Prasad A.N., Rieder M.J. Relationship between antiepileptic drugs and biological markers affecting long-term cardiovascular function in children and adolescents. Can J Clin Pharmacol 2010, 17:e5-e46.
226. Ota K.S. Probablevalproate sodium-associated hypotension. Am J Geriatr Pharmacother 2010, 8:281-284.
227. Lopinto-Khoury C., Mintzer S. Antiepileptic drugs and markers of vascular risk. Curr Treat Options Neurol 2010, 12:300-308.
228. Jahromi S.R., Togha M., Fesharaki S.H., Najafi M., Moghadam N.B., Kheradmand J.A., et al. Gastrointestinal adverse effects of antiepileptic drugs in intractable epileptic patients. Seizure 2011, 20:343-346.
229. Hwang H., Kim H., Kim S.H., Kim S.H., Lim B.C., Chae J.H., et al. Long-term effectiveness of ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. Brain Dev 2012, 34:344-348.
230. Campfield P.R., Bagnell P., Campfield C.S., Tibbles J.A. Pancreatitis due to valproic acid. Lancet 1979, 1:1198-1199.
231. Parker P.H., Helineck G.L., Guisan F.K., Greene H.L. Recurrent pancreatitis induced by valproic acid. Gastroenterology 1981, 80:826-828.
232. Williams L.H.P., Reynolds R.P., Emery J.L. Pancreatitis during sodium valproate treatment. Arch Dis Child 1983, 58:543-545.
233. Vinklerová I., Procházka M., Procházka V., Urbánek K. Incidence, severity, and etiology of drug-induced acute pancreatitis. Dig Dis Sci 2010, 55:2977-2981.
234. Barreto S.G., Tiong L., Williams R. Drug-induced acute pancreatitis in a cohort of 328 patients. A single-centre experience from Australia. JOP 2011, 12:581-585.
235. Guevara-Campos J., González-Guevara L., Vacaro-Bolívar I., Rojas J.M. Acute pancreatitis associated to the use of valproic acid. Arq Neuropsiquiatr 2009, 67:513-515.
236. Santos B.L., Fernandes R.M., Neves F.F. Valproic acid-induced pancreatitis in an adult. Arq Neuropsiquiatr 2010, 68:135-136.
237. Dinopoulos A., Karapanou O., Alexopoulou E., Tzetis M., Attilakos A., Fretzayas A. VPA-induced recurrent pancreatitis in a cystic fibrosis carrier. Eur J Paediatr Neurol 2011, 15:453-455.
238. Choi K.H., Nam T.S., Kim J.T., Choi S.M., Park M.S., Kim B.C., et al. Valproate associated diffuse alveolar hemorrhage. Eur J Neurol 2011, 18:e98-e99.
239. Gupta A., Marrs T., Urquhart D., Clarke S., Rosenthal M., Bush A. Fungal pleural effusion secondary to a rare cause of pancreatic pseudocyst. Pediatr Pulmonol 2009, 44:616-618.
240. Grosso S., Mostardini R., Piccini B., Balestri P. Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy. Ann Pharmacother 2009, 43:45-50.
241. Chang H.H., Yang Y.K., Gean P.W., Huang H.C., Chen P.S., Lu R.B. The role of valproate in metabolic disturbances in bipolar disorder patients. J Affect Disord 2010, 124:319-323.
242. Gaspari C.N., Guerreiro C.A. Modification in body weight associated with antiepileptic drugs. Arq Neuropsiquiatr 2010, 68:277-281.
243. Sharpe C., Wolfson T., Trauner D.A. Weight gain in children treated with valproate. J Child Neurol 2009, 24:338-341.
244. Masuccio F., Verrotti A., Chiavaroli V., de Giorgis T., Giannini C., Chiarelli F., et al. Weight gain and insulin resistance in children treated with valproate: the influence of time. J Child Neurol 2010, 25:941-947.
245. Verrotti A., la Torre R., Trotta D., Mohn A., Chiarelli F. Valproate-induced insulin resistance and obesity in children. Horm Res 2009, 71:125-131.
246. Elmslie J.L., Porter R.J., Joyce P.R., Hunt P.J., Shand B.I., Scott R.S. Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls. Aust N Z J Psychiatry 2009, 43:53-60.
247. Verrotti A., Manco R., Agostinelli S., Coppola G., Chiarelli F. The metabolic syndrome in overweight epileptic patients treated withvalproic acid. Epilepsia 2010, 51:268-273.
248. Liang C.S., Yang F.W., Lo S.M. Rapid development of severe hypertriglyceridemia and hypercholesterolemia during augmentation of quetiapine with valproic acid. J Clin Psychopharmacol 2011, 31:242-243.
249. Chang H.H., Gean P.W., Chou C.H., Yang Y.K., Tsai H.C., Lu R.B., et al. C825T polymorphism of the GNB3 gene on valproate-related metabolic abnormalities in bipolar disorder patients. J Clin Psychopharmacol 2010, 30:512-517.
250. Krepuła K., Bidzińska-Speichert B., Lenarcik A., Tworowska-Bardzińska U. Selected neurologic disorders related to polycystic ovary syndrome. Ginekol Pol 2012, 83:128-131.
251. Verrotti A., Loiacono G., Laus M., Coppola G., Chiarelli F., Tiboni G.M. Hormonal and reproductive disturbances in epileptic male patients: emerging issues. Reprod Toxicol 2011, 31:519-527.
252. Jerrell J.M., Bacon J., Burgis J.T., Menon S. Hyperprolactinemia-related adverse events associated with antipsychotic treatment in children and adolescents. J Adolesc Health 2009, 45:70-76.
253. Leśkiewicz M., Budziszewska B., Lasoń W. Endocrine effects of antiepileptic drugs. Przegl Lek 2008, 65:795-798.
254. Verrotti A., D'Egidio C., Mohn A., Coppola G., Parisi P., Chiarelli F. Antiepileptic drugs, sex hormones, and PCOS. Epilepsia 2011, 52:199-211.
255. Rauchenzauner M., Bitsche G., Svalheim S., Tauboll E., Haberlandt E., Wildt L., et al. Effects of levetiracetam and valproic acid monotherapy on sex-steroid hormones in prepubertal children-results from a pilot study. Epilepsy Res 2010, 88:264-268.
256. Bilo L., Meo R. Polycystic ovary syndrome in women using valproate: a review. Gynecol Endocrinol 2008, 24:562-570.
257. Hu X., Wang J., Dong W., Fang Q., Hu L., Liu C. A meta-analysis of polycystic ovary syndrome in women taking valproate for epilepsy. Epilepsy Res 2011, 97:73-82.
258. Gorkemli H., Genc B.O., Dogan E.A., Genc E., Ozdemir S. Long-term effects of valproic acid on reproductive endocrine functions in Turkish women with epilepsy. Gynecol Obstet Invest 2009, 67:223-227.
259. Beers E., van Puijenbroek E.P., Bartelink I.H., van der Linden C.M., Jansen P.A. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatraemia associated with valproic acid: four case reports from the Netherlands and a case/non-case analysis of vigibase. Drug Saf 2010, 33:47-55.
260. Bève E., Beck E., Pinto E., Ansseau M. Inappropriate antidiuretic hormone secretion induced by sodium valproate. Rev Med Liege 2010, 65:6-9.
261. Sahu J.K., Gulati S., Kabra M., Arya R., Sharma R., Gupta N., et al. Evaluation of subclinical hypothyroidism in ambulatory children with controlled epilepsy on valproate monotherapy. J Child Neurol 2012, 27:594-597.
262. Verrotti A., Laus M., Scardapane A., Franzoni E., Chiarelli F. Thyroid hormones in children with epilepsy during long-term administration of carbamazepine and valproate. Eur J Endocrinol 2009, 160:81-86.
263. Park Y.M., Kang S.G., Lee B.H., Lee H.J. Decreased thyroid function in Korean women with bipolar disorder receiving valproic acid. Gen Hosp Psychiatry 2011, 33:200.e13-5.
264. Bou Khalil R., Richa S. Thyroid adverse effects of psychotropic drugs: a review. Clin Neuropharmacol 2011, 34:248-255.
265. Vainionpää L.K., Mikkonen K., Rättyä J., Knip M., Pakarinen A.J., Myllylä V.V., et al. Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication. Epilepsia 2004, 45:197-203.
266. Yildiz M., Simsek G., Uzun H., Uysal S., Sahin S., Balci H. Assessment of low-density lipoprotein oxidation, paraoxonase activity, and arterial distensibility in epileptic children who were treated with anti-epileptic drugs. Cardiol Young 2010, 20:547-554.
267. Aggarwal A., Rastogi N., Mittal H., Chillar N., Patil R. Thyroid hormone levels in children receiving carbamazepine or valproate. Pediatr Neurol 2011, 45:159-162.
268. Aygün F., Ekici B., Aydinli N., Aydin B.K., Baş F., Tatli B. Thyroid hormones in children on antiepileptic therapy. Int J Neurosci 2012, 122:69-73.
269. Lossius M.I., Taubøll E., Mowinckel P., Gjerstad L. Reversible effects of antiepileptic drugs on thyroid hormones in men and women with epilepsy: a prospective randomized double-blind withdrawal study. Epilepsy Behav 2009, 16:64-68.
270. U.S.Food and Drug Administration Federal Register 1980, 44:37434-37467.
271. U.S.Food and Drug Administration Safety alerts for human medical products: valproate sodium and related products (valproic acid and divalproex sodium): risk of birth defects Accessed Mar 28 2013. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm192788.htm.
272. Wisner K.L., Leckman-Westin E., Finnerty M., Essock S.M. Valproate prescription prevalence among women of childbearing age. Psychiatr Serv 2011, 62:218-220.
273. Crespin S., Bourrel R., Hurault-Delarue C., Lapeyre-Mestre M., Montastruc J.L., Damase-Michel C. Drug prescribing before and during pregnancy in south west France: a retrolective study. Drug Saf 2011, 34:595-604.
274. Ackers R., Besag F.M., Wade A., Murray M.L., Wong I.C. Changing trends in antiepileptic drug prescribing in girls of child-bearing potential. Arch Dis Child 2009, 94:443-447.
275. Vajda F.J., Hollingworth S., Graham J., Hitchcock A.A., O'Brien T.J., Lander C.M., et al. Changing patterns of antiepileptic drug use in pregnant Australian women. Acta Neurol Scand 2010, 121:89-93.
276. Anonymous Valproic acid: long-term effects on children exposed in utero. Prescrire Int 2009, 18:253-257.
277. Genton P., Semah F., Trinka E. Valproic acid in epilepsy: pregnancy-related issues. Drug Saf 2006, 29:1-21.
278. De Santis M., De Luca C., Mappa I., Cesari E., Quattrocchi T., Spagnuolo T., et al. Antiepileptic drugs during pregnancy: pharmacokinetics and transplacental transfer. Curr Pharm Biotechnol 2011, 12:781-788.
279. Eriksson K., Viinikainen K., Mönkkönen A., Aikiä M., Nieminen P., Heinonen S., et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Res 2005, 65:189-200.
280. McVearry K.M., Gaillard W.D., VanMeter J., Meador K.J. A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy Behav 2009, 16:609-616.
281. Reardon W. Rare but real-the effects of sodium valproate in pregnancy. Ir Med J 2011, 104:165-166.
282. Banach R., Boskovic R., Einarson T., Koren G. Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta-analysis of cohort studies. Drug Saf 2010, 33:73-79.
283. Bromley R.L., Mawer G., Love J., Kelly J., Purdy L., McEwan L., et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia 2010, 51:2058-2065.
284. Meador K.J., Baker G.A., Browning N., Clayton-Smith J., Combs-Cantrell D.T., Cohen M., et al. Cognitive function at 3years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009, 360:1597-1605.
285. Battino D. Cognitive outcome after exposure to antiepileptic drugs in utero. Lancet Neurol 2009, 8:600-601.
286. Liu Y.H., Wang L., Huang Y.G. Cognitive function after fetal exposure to antiepileptic drugs. N Engl J Med 2009, 361:629.
287. Nadebaum C., Anderson V., Vajda F., Reutens D., Barton S., Wood A. The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. J Int Neuropsychol Soc 2011, 17:133-142.
288. Karceski S., Pack A. Seizure medications, pregnancy, and breastfeeding. Neurology 2010, 75:e90-e92.
289. Dufour-Rainfray D., Vourc'h P., Tourlet S., Guilloteau D., Chalon S., Andres C.R. Fetal exposure to teratogens: evidence of genes involved in autism. Neurosci Biobehav Rev 2011, 35:1254-1265.
290. Veiby G., Daltveit A.K., Engelsen B.A., Gilhus N.E. Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia 2009, 50:2130-2139.
291. Samrén E.B., van Duijn C.M., Koch S., Hiilesmaa V.K., Klepel H., Bardy A.H., et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997, 38:981-990.
292. Wide K., Winbladh B., Källén B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 2004, 93:174-176.
293. Jentink J., Loane M.A., Dolk H., Barisic I., Garne E., Morris J.K., et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010, 362:2185-2193.
294. Gilboa S.M., Broussard C.S., Devine O.J., Duwe K.N., Flak A.L., Boulet S.L., et al. Influencing clinical practice regarding the use of antiepileptic medications during pregnancy: modeling the potential impact on the prevalences of spina bifida and cleft palate in the United States. Am J Med Genet C Semin Med Genet 2011, 157:234-246.
295. Werler M.M., Ahrens K.A., Bosco J.L., Mitchell A.A., Anderka M.T., Gilboa S.M., et al. Use of antiepileptic medications in pregnancy in relation to risks of birth defects. Ann Epidemiol 2011, 21:842-850.
296. Lisi A., Botto L.D., Robert-Gnansia E., Castilla E.E., Bakker M.K., Bianca S., et al. Surveillance of adverse fetal effects of medications (SAFE-Med): findings from the international Clearinghouse of birth defects surveillance and research. Reprod Toxicol 2010, 29:433-442.
297. Alessandri J.L., Isidor B., David A., Martin-Coignard D., Ghazouani J., Ramful D., et al. Tibial developmental field defect in valproic acid embryopathy: report on three cases. Am J Med Genet A 2010, 152A:2805-2809.
298. Cole R.L., Van Ross E.R., Clayton-Smith J. Fibular aplasia in a child exposed to sodium valproate in pregnancy. Clin Dysmorphol 2009, 18:37-39.
299. Ozkan H., Cetinkaya M., Köksal N., Yapici S. Severe fetal valproate syndrome: combination of complex cardiac defect, multicystic dysplastic kidney, and trigonocephaly. J Matern Fetal Neonatal Med 2011, 24:521-524.
300. Vajda F., O'Brien T. Valproic acid use in pregnancy and congenital malformations. N Engl J Med 2010, 363:1771.
301. Vajda F.J., Hitchcock A., Graham J., Solinas C., O'Brien T.J., Lander C.M., et al. Foetal malformations and seizure control: 52months data of the Australian Pregnancy Registry. Eur J Neurol 2006, 13:645-654.
302. Mawhinney E., Campbell J., Craig J., Russell A., Smithson W., Parsons L., et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?. Seizure 2012, 21:215-218.
303. Tomson T., Battino D., Bonizzoni E., Craig J., Lindhout D., Sabers A., et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011, 10:609-617.
304. Morrow J., Russell A., Guthrie E., Parsons L., Robertson I., Waddell R., et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006, 77:193-198.
305. Wlodarczyk B.J., Palacios A.M., George T.M., Finnell R.H. Antiepileptic drugs and pregnancy outcomes. Am J Med Genet A 2012, 158A:2071-2090.
306. Vajda F.J., Hitchcock A.A., Graham J., O'Brien T.J., Lander C.M., Eadie M.J. The teratogenic risk of antiepileptic drug polytherapy. Epilepsia 2010, 51:805-810.
307. Sabers A., Larsen K., Blichfeldt S., Sahlholdt L., Rasmussen J.O. Valproate treatment during pregnancy: description of four cases with foetal valproate syndrome. Ugeskr Laeger 2009, 171:221-225.
308. Seidahmed M.Z., Miqdad A.M., Al-Dohami H.S., Shareefi O.M. A case of fetal valproate syndrome with new features expanding the phenotype. Saudi Med J 2009, 30:288-291.
309. Zaki S.A., Phulsundar A., Shanbag P., Mauskar A. Fetal valproate syndrome in a 2-month-old male infant. Ann Saudi Med 2010, 30:233-235.
310. Meador K.J., Baker G.A., Browning N., Clayton-Smith J., Combs-Cantrell D.T., Cohen M., et al. Effects of breastfeeding in children of women taking antiepileptic drugs. Neurology 2010, 75:1954-1960.
311. Klein A. Antiepileptic drugs and breastfeeding: do we tell women "no"?. Neurology 2010, 75:1948-1949.